Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.

Cancer treatment and research communications·2022
Same author

[Retinal detachment in children and adolescents. Specific clinical features].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2019
Same author

Comparison of Two Toric IOL Calculation Methods.

Journal of ophthalmology·2018
Same author

[Smart eye data : Development of a foundation for medical research using Smart Data applications].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2016
Same author

Price Negotiation For Pharmaceuticals in Germany: High Influence Of Eu Price Weighting Method.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

[Economic Short-Term Cost Model for Stereotactic Radiotherapy of Neovascular AMD].

Klinische Monatsblatter fur Augenheilkunde·2016
Same journal

["DOG 2020 online" - for the first time in the von Graefe year].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2024
Same journal

[Are organ and co-cultures an alternative to animal models in ophthalmology?]

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Pediatric corneal opacities : Even small improvements provide lifelong help].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Myxoma of the conjunctiva].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Secondary open-angle glaucoma: uveitic secondary glaucoma, steroid-induced glaucoma, posttraumatic and postoperative glaucoma, tumor-related glaucoma and glaucoma due to elevated episcleral venous pressure].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Artificial intelligence in the management of anti-VEGF treatment: the Vienna fluid monitor in clinical practice].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

[Value-based medicine for glaucoma].

C Hirneiss1, A Kampik, A S Neubauer

  • 1Augenklinik der Ludwig-Maximilians-Universität, München, Deutschland. Christoph.Hirneiss@med.uni-muenchen.de

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|February 26, 2010
PubMed
Summary
This summary is machine-generated.

Value-based medicine in glaucoma research needs quality of life data. Instruments must capture peripheral vision loss to inform cost-utility analyses for efficient treatment strategies.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Related Experiment Videos

Last Updated: Jun 15, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Area of Science:

  • Ophthalmology and Health Economics
  • Value-based medicine (VBM) application in clinical research

Context:

  • Glaucoma research necessitates robust quality of life (QoL) data for effective value-based medicine (VBM) implementation.
  • Existing QoL instruments for glaucoma patients vary, requiring careful selection for research validity.
  • Peripheral vision loss is a key disease manifestation impacting patient-reported QoL.

Purpose:

  • To review the necessity of reliable QoL data in glaucoma research for VBM.
  • To highlight the importance of capturing peripheral vision loss in QoL assessments.
  • To establish the foundation for cost-utility analyses in glaucoma management.

Summary:

  • Value-based medicine (VBM) in glaucoma requires validated QoL measures.
  • Instruments must assess peripheral vision loss and its impact on patient QoL.
  • QoL data combined with treatment costs enables cost-utility analyses.

Impact:

  • Facilitates evidence-based recommendations for cost-efficient glaucoma screening and treatment.
  • Supports the integration of patient-reported outcomes into clinical decision-making.
  • Enhances the economic evaluation of interventions for glaucoma and ocular hypertension.